BRCA1 and ovarian cancer: For examples, ovary cancer patients with BRCA1 or BRCA2 mutations benefit particularly from Poly ADP-ribose polymerase inhibitor Olaparib while solid tumors with MMR mutations have demonstrated high response rate to immune checkpoint blockade3,4.